A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Public ClinicalTrials.gov record NCT06179160. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Study identification
- NCT ID
- NCT06179160
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Incyte Corporation
- Industry
- Enrollment
- 710 participants
Conditions and interventions
Conditions
Interventions
- Cetuximab Drug
- FOLFIRI Drug
- FOLFOX Drug
- GEMNabP Drug
- INCA33890 Drug
- INCB161734 Drug
- Retifanlimab Drug
- mFOLFIRINOX Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 3, 2024
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
- Last update posted
- May 3, 2026
2024 – 2027
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Hospital | Phoenix | Arizona | 85054 | Recruiting |
| Stanford University | Palo Alto | California | 94305 | Recruiting |
| UCLA Healthcare Hematology-Oncology | Santa Monica | California | 90404 | Recruiting |
| Sarah Cannon Research Institue At Healthone | Denver | Colorado | 80218 | Recruiting |
| Mayo Clinic Florida | Jacksonville | Florida | 32224 | Withdrawn |
| Florida Cancer Specialists | Sarasota | Florida | 34232 | Withdrawn |
| Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins | Baltimore | Maryland | 21287 | Recruiting |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
| Mayo Clinic | Rochester | Minnesota | 55905 | Withdrawn |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | Recruiting |
| Weill Cornell Medicine | New York | New York | 10021 | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10022 | Recruiting |
| Jefferson University Hospitals | Philadelphia | Pennsylvania | 19107 | Recruiting |
| Scri Oncology Partners | Nashville | Tennessee | 37203 | Recruiting |
| Md Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06179160, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 3, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06179160 live on ClinicalTrials.gov.